Krystal Biotech, Inc. (KRYS) Financials
KRYS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 818.4 million | 39.7 million |
2023-09-30 | 790.4 million | 34.4 million |
2023-06-30 | 684.0 million | 30.9 million |
2023-03-31 | 531.8 million | 42.3 million |
KRYS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -9.1 million | 9.9 million |
2023-09-30 | -23.0 million | 8.3 million |
2023-06-30 | -37.0 million | 11.3 million |
2023-03-31 | -31.5 million | 10.4 million |
KRYS Net Income
No data available :(
KRYS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 532.2 million | - | 8.1 million |
2023-09-30 | 562.1 million | - | 8.3 million |
2023-06-30 | 477.5 million | - | 8.5 million |
2023-03-31 | 350.4 million | - | 8.8 million |
KRYS Shares Outstanding
KRYS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 1.8 million | 11.4 million | 24.8 million | - |
2023-09-30 | 1.8 million | 10.6 million | 23.7 million | - |
2023-06-30 | 2.8 million | 12.1 million | 25.9 million | - |
2023-03-31 | 5.4 million | 12.3 million | 24.0 million | - |
KRYS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 42.1 million | 4.4 million |
2023-09-30 | 8.6 million | 223000 |
2023-06-30 | - | 1.2 million |
2023-03-31 | - | 1.1 million |
KRYS
Price: $159.67
52 week price:
Earnings Per Share: 0.38 USD
P/E Ratio: -94.90
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 151900
Ebitda: -2.1 millionMarket Capitalization: 4.8 billion